These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 31584575)

  • 21. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
    Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
    Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
    Roman M; Chiu MW
    Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brodalumab in the treatment of chronic plaque psoriasis.
    Gisondi P; Girolomoni G
    Expert Opin Biol Ther; 2020 Oct; 20(10):1175-1186. PubMed ID: 32463723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-IL-17 phase II data for psoriasis: A review.
    Brown G; Malakouti M; Wang E; Koo JY; Levin E
    J Dermatolog Treat; 2015 Feb; 26(1):32-6. PubMed ID: 24552447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

  • 28. New and emerging therapies in psoriasis.
    Leonardi CL; Gordon KB
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
    Tong Y; Peranteau AJ; Nawas Z; Tyring SK
    Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
    Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
    Menter A; Van Voorhees AS; Hsu S
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.
    Vidal S; Puig L; Carrascosa-Carrillo JM; González-Cantero Á; Ruiz-Carrascosa JC; Velasco-Pastor AM
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological therapy for pustular psoriasis: a systematic review.
    Falto-Aizpurua LA; Martin-Garcia RF; Carrasquillo OY; Nevares-Pomales OW; Sánchez-Flores X; Lorenzo-Rios D
    Int J Dermatol; 2020 Mar; 59(3):284-296. PubMed ID: 31612467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis.
    Bauer E; Lucier J; Furst DE
    Expert Opin Biol Ther; 2015 Jun; 15(6):883-93. PubMed ID: 25985813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.
    Chiricozzi A; Romanelli M; Saraceno R; Torres T
    Expert Opin Drug Saf; 2016 Dec; 15(12):1653-1659. PubMed ID: 27554637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.